Jonathan Gill

The Paf oncogene is essential for hematopoietic stem cell function and development.

Inherited hematologic and oncologic syndromes.

Operative experience of urological trainees in the UK.

Anatomical constraints on attention: hemifield independence is a signature of multifocal spatial selection.

New targets and approaches in osteosarcoma.

β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells.

Visual long-term memory has the same limit on fidelity as visual working memory.

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

Photoaffinity labeling the propofol binding site in GLIC.

Morphological and functional remodelling of the neuromuscular junction by skeletal muscle PGC-1α.

HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.

Advances in therapy for pediatric sarcomas.

HER-2 involvement in osteosarcoma.

Orthotopic neobladder perforation: an unusual presentation of small bowel obstruction.

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.

Frequent urination causing sleepless nights in a 64-year-old man.

Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2.

Pediatric primary splenic angiosarcoma: an aggressive multidisciplinary approach to the oncologic management of a rare malignancy.

Variability in the reported management of pulmonary metastases in osteosarcoma.

Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma.

Yolk sac tumor of the seminal vesicles: A rare malignant cause of hematospermia.

Reconstruction of the pediatric midface following oncologic resection.

Spontaneous right-sided ureterocolic fistula: a rare complication of colonic diverticular disease.

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

To B(MP-2) or Not To B(MP-2): Cytokines and Tumor Surgery—Letter.

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.